StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Abbvie (ABBV) Humira guidance removes overhang - Truist
February 9, 2023 1:39 PM
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $180.00 price target on Abbvie (NYSE: ABBV) as Humira guidance ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Next Articles
CFRA Downgrades Abbvie (ABBV) to Sell
February 9, 2023 12:14 PM
Form SC 13G/A AbbVie Inc. Filed by: VANGUARD GROUP INC
February 9, 2023 10:56 AM
AbbVie (ABBV) In Position To Pursue Larger M&A: CEO Gonzalez - Bloomberg
February 9, 2023 10:04 AM
AbbVie (ABBV) shares rise on earnings beat - prepared for loss of Humira exclusivity
February 9, 2023 10:00 AM
Form 8-K AbbVie Inc. For: Feb 09
February 9, 2023 7:55 AM
Disney delights, consumer earnings, jobless claims - what's moving markets
February 9, 2023 7:51 AM
AbbVie sees 37% drop in Humira sales this year as biosimilars hit U.S. market
February 9, 2023 7:50 AM
AbbVie (ABBV) Tops Q4 EPS by 7c, Offers Guidance
February 9, 2023 7:46 AM
